ADAPTIVEMOBILE-SECURITY
12.9.2019 09:09:08 CEST | Business Wire | Press release
Following extensive research, AdaptiveMobile Security, a world leader in cyber-telecoms security, today announced it has uncovered a new and previously undetected vulnerability. This vulnerability is currently being exploited and is being used for targeted surveillance of mobile phone users. The vulnerability and its associated attacks have been named, ‘Simjacker’ as it involves the hijacking of SIM cards and threatens mobile phone users across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005038/en/
Simjacker extracts the location information of mobile phone users from vulnerable operators, retrieved using malicious SMS messages. The location information of thousands of devices was obtained over time without the knowledge or consent of the targeted mobile phone users. Based on previous intelligence, it is likely that these attacks originated from a surveillance company which works with governments, to track and monitor individuals; bypassing existing signalling protection.
Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security explained, “Simjacker represents a clear danger to the mobile operators and subscribers. This is potentially the most sophisticated attack ever seen over core mobile networks. It’s a major wake-up call that shows hostile actors are investing heavily in increasingly complex and creative ways to undermine network security. This compromises the security and trust of customers, mobile operators and impacts the national security of entire countries.”
While the primary attack detected involved the retrieval of mobile phone locations, Simjacker has been further exploited to perform many other types of attacks against individuals and mobile operators such as fraud, scam calls, information leakage, denial of service and espionage. AdaptiveMobile Security Threat Intelligence analysts observed the hackers vary their attacks, testing many of these further exploits.
In theory, all makes and models of mobile phone are open to attack as the vulnerability is linked to a technology embedded on SIM cards. AdaptiveMobile Security research indicates that the Simjacker vulnerability could extend to over 1 billion mobile phone users globally, potentially impacting countries in North and South America, West Africa, Europe, Middle East and indeed any region of the world where this SIM card technology is in use.
Mc Daid continued, “Simjacker worked so well and was being successfully exploited for years because it took advantage of a combination of complex interfaces and obscure technologies, showing that mobile operators cannot rely on standard established defences. Now that this vulnerability has been revealed, we fully expect the exploit authors and other malicious actors will try to evolve these attacks into other areas”.
AdaptiveMobile Security has been working closely with their customers and the wider industry; including both mobile network operators and SIM card manufacturers to protect mobile phone subscribers. AdaptiveMobile Security are committed to using their global threat intelligence to build defences against these new sophisticated attacks that are circumventing current security measures.
Further details on Simjacker are available on www.simjacker.com and Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security will be presenting on Simjacker at the Virus Bulletin Conference, London, 3 October 2019.
---Ends---
About
AdaptiveMobile Security is the world leader in cyber-telecoms security, protecting over 2.1 billion subscribers worldwide. The combination of global insight provided by our security specialists teams, our world-leading Threat Intelligence Unit and our proprietary, telecom-grade Network Protection Platform are trusted by the world’s largest service providers to secure their critical communications infrastructure.
The Company HQ is in Dublin with offices in North America, Europe, South Africa, the Middle East and Asia Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
